DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for urethra squamous cell carcinoma — screening already-approved drugs against its 11-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleUrethra squamous cell carcinoma maps to a 11-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for urethra squamous cell carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) — PIK3CA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4JPS · 2.2 Å · ligand (2S)-N~1~-{4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide (1LT). Experimental structure, not a prediction.
What the evidence adds up to
A 1976 review of 81 female urethral carcinoma cases reported an overall 5-year and 10-year survival rate of 32 per cent. Squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma showed similar survival when analysed by stage, and all cell types appeared to respond equally to irradiation. Local recurrence after any single-modality therapy ranged from 46 to 64 per cent. A 1997 review stated that early distal urethral squamous cancers could achieve 70–80 per cent 5-year survival with surgery or 75 per cent with brachytherapy; for advanced cancers, a combination of radiation and chemotherapy was described as the optimal approach, with surgery reserved for persistent or recurrent disease.
Two case reports from 2013 described male and female patients with urethral squamous cell carcinoma treated with concomitant cisplatin and radiotherapy. The authors noted that these cases added to a body of reports showing benefit for chemoradiotherapy, and that single-agent cisplatin could be used with limited toxicities. A 2020 case report reiterated that treatment is essentially surgical but often mutilating, and that the prognosis remains unfavourable in most cases, with current hope placed on combining chemotherapy and radiotherapy.
A 2025 exploratory study compared gene expression in 13 urethral cancer specimens against 10 histologically normal urethral tissues from penile cancer patients. RNA sequencing identified 1,212 significantly differentially expressed genes (false discovery rate <0.01). Enriched pathways included chromosome organisation, cell cycle regulation, nuclear division, tissue development, and enhanced viral protein interactions. The authors concluded that next-generation sequencing revealed several commonly altered genes and pathways and offered new targets for future diagnostic and therapeutic trials.
What is still missing are prospective randomised trials, which are absent for this rare cancer. The evidence base remains limited to retrospective reviews, case series, and small exploratory molecular studies. No validated biomarkers for patient stratification exist, and no targeted therapies have been tested in a controlled setting. Funding for multi-centre trials and systematic molecular profiling of larger cohorts is lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Epidemiology · 1984 · 274 citations
URINARY TRACT INFECTION AND RISK OF BLADDER CANCER
AbstractIn an epidemiologic study of 2982 bladder carcinoma patients and 5782 population controls from 10 geographic areas of the United States, the role of urinary tract infection and inflammation in the etiology of this neoplasm was evaluated. A history of urinary tract infection significantly elevated the risk of bladder cancer, particularly in individuals who reported three or more infections (relative risk (RR) = 2.0). Significantly increased bladder cancer risk was also found for bladder stones (RR = 1.8), while kidney stones showed no relation. A history of three or more urinary tract infections was strongly related to squamous cell carcinoma in particular (RR = 4.8).
AbstractThe clinical and morphological features in 81 cases of carcinoma of the female urethra were reviewed. The over-all 5 and 10-year survival rate for the entire group was 32 per cent. Survival expectations for patients with squamous carcinoma, transitional cell carcinoma and adenocarcinoma were similar when analyzed according to stage and all cell types appeared to respond equally to irradiation. Prognosis was related directly to the clinical stage of the disease. A plea is made for more accurate assessment of the disease status. The high incidence of local recurrence noted for all forms of single modality therapy (46 to 64 per cent) suggests the need for clinical trials with combination preoperative irradiation followed by definitive surgical procedures.
Seminars in Surgical Oncology · 1997 · 26 citations
Brachytherapy for cancer of the female urethra
AbstractCarcinoma of the female urethra is uncommon. The review of literature and our own experience indicates that early distal urethral cancers (squamous and adenocarcinoma) can be treated either with surgery (70-80% 5-year survival) or with radiotherapy (brachytherapy) with excellent results (75% 5-year survival). Early proximal or entire urethral cancers (squamous and adenocarcinoma), if treated surgically, will require exenterative procedures. Alternatively, these cancers can be treated with a combination of external beam and brachytherapy with or without chemotherapy with good results and preservation of organs. Surgery can be used for failures or persistent tumors. Advanced cancers require a multimodality approach, and a combination of radiation and chemotherapy appears to be the optimal way to treat these patients-with surgery to be used for biopsy-proven persistent tumors or recurrences.
Asia-Pacific Journal of Clinical Oncology · 2015 · 8 citations · open access
Safety and efficacy of sunitinib for advanced non‐clear cell renal cell carcinoma
AbstractAIM: This study evaluated the safety and efficacy of sunitinib in the treatment of advanced non-clear cell renal cell carcinoma. METHODS: Thirty-seven Chinese patients with advanced non-clear cell renal cell carcinoma were enrolled from October 2008 to October 2013. Sunitinib monotherapy was administered in repeated 6-week cycles of daily oral administration of 50 mg for 4 weeks, followed by 2 weeks off. Computed tomography scan was used to evaluate the efficacy every two cycles. RESULTS: All 37 patients received sunitinib treatment according to the schedule and were evaluated for response and toxicity. Thirty (81.1%) patients underwent nephrectomy before sunitinib treatment and seven (18.9%) patients had kidney biopsy. Twenty-five patients were diagnosed with papillary renal cell carcinoma, two with spindle cell-type renal cell carcinoma, two with chromophobe renal cell carcinoma and eight with unclassified cell types. The disease control rate was 73.0%, with partial response in 5 (13.5%), stable disease in 22 (59.5%) and progression disease in 10 (27.0%), the best tumor response. The median progression-free survival (PFS) was 6 months and the median overall survival (OS) was 9 months. In patients with papillary renal cell carcinoma, the median PFS was 6 months and the median OS was 10 months. The most common adverse events were hand-foot syndrome, fatigue, leukopenia, anemia, thrombocytopenia, mucositis, edema and hypertension. All adverse events were ameliorated by supportive treatment, dose reduction or treatment interruption. CONCLUSION: Sunitinib was efficacious in the treatment of advanced non-clear cell renal cell carcinoma. Most adverse events were tolerable.
Case Reports in Urology · 2013 · 7 citations · open access
Radical Chemoradiotherapy for Urethral Squamous Cell Carcinoma: Two Case Reports and a Review of the Literature
AbstractPrimary urethral squamous cell carcinoma is rare. Its management is particularly challenging owing to the paucity of evidence from randomised trials to inform practice. We report two male and female cases of squamous cell carcinoma of the urethra, which were treated with concomitant cisplatin and radiotherapy. These cases add to the body of case reports that have shown benefit for concomitant chemoradiotherapy in urethral squamous cell carcinoma. They also illustrate that single agent chemotherapy, namely, cisplatin, may be used successfully with limited toxicities.
World Journal of Innovative Research · 2020 · 0 citations · open access
A Challenging Nonsurgical Management to Locally Advanced Urethral Squamous Cell Carcinoma
AbstractUrethral squamous cell carcinoma (SCC) is a rare entity, comprising less than 1% of all cancers. The diagnosis is often late because the symptomatology is not specific. Its treatment is essentially surgical but often mutilating. The prognosis remains unfavorable in the majority of cases. The current hope is the combination of chemotherapy and radiotherapy.
Next-Generation Sequencing Reveals Differentially Expressed Genes and Pathways in Urethral Cancer: Exploring A Poorly Understood Malignancy
AbstractPurpose: Primary urethral cancer (PUC) is an uncommon malignancy with scarce diagnostic and treatment options, resulting in a limited understanding of its genetic foundation. This exploratory study compares gene expression profiles between urethral cancer and histologically normal urethral tissue from penile cancer patients (HN-PC).Materials and Methods: Twenty-three urethral specimens (13 malignant and 10 HN-PC) were collected between 2015 and 2023. RNA was isolated and analyzed via bulk RNA sequencing. Differentially expressed genes were identified, and multiple enrichment analysis techniques were performed including gene set enrichment analysis (GSEA), gene ontology analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis.Results: A total of 1,212 significantly differentially expressed genes (false discovery rate [FDR] <0.01) were recognized with strong differentiation between the 2 cohorts. Twenty-two GSEA gene sets were identified as significantly enriched (FDR <0.01) with 392 significantly upregulated (FDR <0.01 and log2 fold change >1) genes within the leading edges. Gene ontology analysis highlighted chromosome organization, cell cycle regulation/processes, nuclear division, and tissue development. KEGG analysis revealed similar findings with the addition of enhanced viral protein interactions.Conclusion: Next-generation sequencing revealed several genes and pathways commonly altered in PUC and also offered a set of new targets for future diagnostic and therapeutic trials.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
